Analysis of hospital activity, costs and income following allogeneic stem cell transplantation in England

to exploring new payment models to help ensure that The costs incurred between 100 days and 365 days patients receive the right care, in the right place, at after discharge were £70.0mn nationally (30%) and the right time. [...] To start filling this gap in the evidence base, EY was Despite the limitations of our analysis, which are commissioned by Anthony Nolan to independently explained in detail in this report, these findings conduct an initial analysis of the hospital activity and suggest that the current payment model for stem cell costs associated with allogeneic stem cell transplant transplantation may benefit from. [...] To start filling this gap in the evidence base, EY was commissioned by Anthony Nolan to independently conduct an initial analysis of the hospital activity and costs associated with allogeneic stem cell transplant patients in the 365 days after discharge. [...] Confidential – All Rights Reserved Analysis of hospital activity, costs and income following allogeneic stem cell transplantation in England | 5 Approach Two sources of data were used to analyse the hospital activity and costs associated with allogeneic stem cell transplant patients in the 365 days after discharge: NHS Digital’s Secondary Uses Service (SUS) data and The Royal Marsden NHS Foundatio. [...] This is why our analysis considers the 365 days after discharge (broken down into the first 100 days, the next 100 days and the 165 days after that), rather than the 365 days post-transplant.